{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tapentadol",
    "query": {
      "intervention": "Tapentadol"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 21,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tapentadol&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T11:29:19.242Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01981278",
      "title": "A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Tapentadol ER 250-mg TRF tablet",
          "type": "DRUG"
        },
        {
          "name": "Tapentadol ER 250-mg PR2 tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 63,
      "start_date": "2010-07",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2013-11-14",
      "last_synced_at": "2026-09-04T11:29:19.242Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01981278"
    },
    {
      "nct_id": "NCT01063868",
      "title": "A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Neuropathy, Painful",
        "Diabetic Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "Tapentadol extended release (ER)",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone controlled release (CR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2010-01",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2014-03-04",
      "last_synced_at": "2026-09-04T11:29:19.242Z",
      "location_count": 23,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • Fruitland Park, Florida + 20 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fruitland Park",
          "state": "Florida"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Oviedo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01063868"
    },
    {
      "nct_id": "NCT01729728",
      "title": "Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postoperative Pain",
        "Acute Pain"
      ],
      "interventions": [
        {
          "name": "Tapentadol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Grünenthal GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 86,
      "start_date": "2012-11",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2019-11-04",
      "last_synced_at": "2026-09-04T11:29:19.242Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01729728"
    },
    {
      "nct_id": "NCT01500317",
      "title": "Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Effects of 2 Mu-opiates on Gastrointestinal Transit"
      ],
      "interventions": [
        {
          "name": "Tapentadol",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 38,
      "start_date": "2011-05",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2012-12-17",
      "last_synced_at": "2026-09-04T11:29:19.242Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01500317"
    },
    {
      "nct_id": "NCT02019485",
      "title": "A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF)",
          "type": "DRUG"
        },
        {
          "name": "Tapentadol Prolonged-Release Formulation 2 (PR2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 64,
      "start_date": "2010-07",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2013-12-24",
      "last_synced_at": "2026-09-04T11:29:19.242Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02019485"
    },
    {
      "nct_id": "NCT00613938",
      "title": "A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthralgia",
        "Bunion",
        "Hallux Valgus",
        "Pain"
      ],
      "interventions": [
        {
          "name": "Tapentadol (CG5503)",
          "type": "DRUG"
        },
        {
          "name": "oxycodone",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 901,
      "start_date": "2008-02",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2014-05-09",
      "last_synced_at": "2026-09-04T11:29:19.242Z",
      "location_count": 7,
      "location_summary": "Glendale, California • Pasadena, Maryland • Austin, Texas + 4 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "Maryland"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00613938"
    },
    {
      "nct_id": "NCT01631513",
      "title": "An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain",
        "Chronic Back Pain",
        "Chronic Low Back Pain",
        "Osteoarthritis Pain In The Hip or Knee"
      ],
      "interventions": [
        {
          "name": "Nucynta ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 0,
      "start_date": "2012-08",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2018-01-25",
      "last_synced_at": "2026-09-04T11:29:19.242Z",
      "location_count": 7,
      "location_summary": "Jacksonville, Florida • Prairie Village, Kansas • Mandeville, Louisiana + 4 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Prairie Village",
          "state": "Kansas"
        },
        {
          "city": "Mandeville",
          "state": "Louisiana"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01631513"
    },
    {
      "nct_id": "NCT01900587",
      "title": "A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Tapentadol ER Tamper-resistant Formulation (TRF)",
          "type": "DRUG"
        },
        {
          "name": "Tapentadol ER Prolonged-Release 2 (PR2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 64,
      "start_date": "2010-07",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2013-11-01",
      "last_synced_at": "2026-09-04T11:29:19.242Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01900587"
    },
    {
      "nct_id": "NCT00505414",
      "title": "A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain",
        "Neoplasm",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Tapentadol in the Titration Phase",
          "type": "DRUG"
        },
        {
          "name": "Morphine in the Maintenance Phase",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase",
          "type": "DRUG"
        },
        {
          "name": "Tapentadol in the Maintenance Phase",
          "type": "DRUG"
        },
        {
          "name": "Morphine in the Titration Phase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Grünenthal GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 136,
      "start_date": "2007-06",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2019-11-01",
      "last_synced_at": "2026-09-04T11:29:19.242Z",
      "location_count": 7,
      "location_summary": "St. Petersburg, Florida • Elkhart, Indiana • Shreveport, Louisiana + 4 more",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Elkhart",
          "state": "Indiana"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Cedarhurst",
          "state": "New York"
        },
        {
          "city": "Glens Falls",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00505414"
    },
    {
      "nct_id": "NCT00487435",
      "title": "An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain",
        "Osteoarthritis",
        "Low Back Pain"
      ],
      "interventions": [
        {
          "name": "Tapentadol (CG5503) Extended Release (ER)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1166,
      "start_date": "2007-06",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2014-05-09",
      "last_synced_at": "2026-09-04T11:29:19.242Z",
      "location_count": 118,
      "location_summary": "Birmingham, Alabama • Hoover, Alabama • Mobile, Alabama + 115 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00487435"
    }
  ]
}